Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary vs intravenous abciximab during primary PCI for STEMI
2007-007864-63Phase 3Completed
- Sponsor
- Leipzig University
- Start
- Feb 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of abciximab in myocardial infarction (MI) (2 arms), sponsored by Leipzig University. Primary endpoint: Combined clinical endpoint at 90 days. Started Feb 2008; status: completed.
02
Drugs
abciximab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2007-007864-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007864-63.